Skip to main content
SpringerLink
Log in

Deferoxamine

  • Reference work entry
  • First Online:
Critical Care Toxicology

  • 256 Accesses

Abstract

Deferoxamine is a chelator used for acutely ill iron-poisoned patients. It can also be used as an aluminum chelator and in the treatment of transfusional iron overload states. Its use in critically-ill patients is, however, almost always confined to patients with acute iron overdose. The treatment of acute iron toxicity is discussed in detail in the “Iron” chapter. This chapter focuses on the clinical pharmacology of deferoxamine for the treatment of acute iron poisoning.

The original version of this chapter was revised: An erratum to this chapter can be found at DOI 10.1007/978-3-319-17900-1_186.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 338.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758–68.

    Article  CAS  PubMed  Google Scholar 

  2. Moeschlin S, Schnider U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new potent iron eliminating agent (desferrioxamine-B). N Engl J Med. 1963;269:57–66.

    Article  Google Scholar 

  3. Westlin W. Deferoxamine in the treatment of acute iron poisoning: clinical experiences with 172 children. Clin Pediatr. 1966;5:531–5.

    Article  CAS  Google Scholar 

  4. Westlin W. Deferoxamine as a chelating agent. Clin Toxicol. 1971;4:597–602.

    Article  CAS  PubMed  Google Scholar 

  5. Hershko C, Konijn AM, Ling G. Iron chelators for thalassemia. Br J Haematol. 1998;101:399–406.

    Article  CAS  PubMed  Google Scholar 

  6. Cabantchik ZL, Milgram P, Glickstein H, et al. A method for assessing iron chelation in membrane model systems and in living mammalian cells. Anal Biochem. 1995;233:221–7.

    Article  Google Scholar 

  7. Zannineli G, Glickstein H, Breuer W, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842–52.

    Google Scholar 

  8. Pollack S, Vanderhoff G, Lasky F. Iron removal from transferrin – an experimental study. Biochim Biophys Acta. 1977;497:481–7.

    Article  CAS  PubMed  Google Scholar 

  9. Breuer W, Ermers MJ, Pootrakul P, et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792–8.

    Article  CAS  PubMed  Google Scholar 

  10. Barry M, Flynn DM, Letsky EA, et al. Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology, and clinical prograss. BMJ Clin Res. 1974;2:16–20.

    Article  CAS  Google Scholar 

  11. Porter JB. Deferoxamine pharmacokinetics. Semin Hematol. 2001;38:63–8.

    Article  CAS  PubMed  Google Scholar 

  12. Bentur Y, Koren G, Klein J, et al. Pharmacokinetics of deferoxamine with and without iron load. Vet Hum Toxicol. 1989;31:156–7.

    CAS  PubMed  Google Scholar 

  13. Lee P, Mohammed N, Abeysinghe RD, et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients. Drug Metab Dispos. 1993;21:640–4.

    CAS  PubMed  Google Scholar 

  14. Singh S, Hider RC, Porter JB. Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry. Anal Biochem. 1990;187:1–8.

    Article  Google Scholar 

  15. Singh S, Mohammed N, Ackerman R, et al. Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet–visible/radioactive detection. Anal Biochem. 1992;203:116–20.

    Article  CAS  PubMed  Google Scholar 

  16. Allain P, Mauras Y, Chaleil D, et al. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol. 1987;24:207–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Peter G, Keberle M, Schmid K. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat. Biochem Pharmacol. 1966;15:93–109.

    Article  Google Scholar 

  18. Richardson JR, Sugerman DL, Hulet WH. Extraction of iron by chelation with desferrioxamine and hemodialysis. Clin Res. 1967;15:368.

    Google Scholar 

  19. Banner Jr W, Vernon DD, Ward RM, et al. Continuous arteriovenous hemofiltration in experimental iron intoxication. Crit Care Med. 1989;17:1187–90.

    Article  PubMed  Google Scholar 

  20. Ceriati F, Pomponi M, Cavicchioni C, et al. Continuous intra-venous (CIV) infusion of deferoxamine (DF) in a hemodialysed patient with transfusion or siderosis (Letter). Int J Artif Organs. 1981;4:409.

    Google Scholar 

  21. McGonigle RJS, Keogh AM, Weston MJ, et al. Iron status in chronic hemodialysis patients: treatment of transfusional iron overload with desferrioxamine. Dial Transplant. 1984;13:214.

    Google Scholar 

  22. Hilfenhaus M, Koch KM, Bechstein PB, et al. Therapy and monitoring of hypersiderosis in chronic renal insufficiency. Contrib Nephrol. 1984;38:167–74.

    Article  CAS  PubMed  Google Scholar 

  23. Rayburn WF, Donna SM, Wulf ME. Iron overdose during pregnancy: successful therapy with deferoxamine. Am J Obstet Gynecol. 1983;147:717–8.

    Article  CAS  PubMed  Google Scholar 

  24. Blanc P, Hryhorczuk D, Danel I. Deferoxamine treatment of acute iron intoxication in pregnancy. Obstet Gynecol. 1984;64:125–45.

    Article  Google Scholar 

  25. Thomas RM, Skalicka AE. Successful pregnancy in transfusion-dependent thalassaemia. Arch Dis Child. 1980;55:572–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol. 1999;60:24–6.

    Article  CAS  PubMed  Google Scholar 

  27. Martin K. Successful pregnancy in β-thalassaemia major. Aust Pediatr J. 1983;19:182–3.

    CAS  Google Scholar 

  28. Curry SC, Bond GR, Raschke R, et al. An ovine model of maternal iron poisoning in pregnancy. Ann Emerg Med. 1990;19:632–8.

    Article  CAS  PubMed  Google Scholar 

  29. Bentur Y, McGuigan M, Koren G. Deferoxamine (desferrioxamine) new toxicities for an old drug. Drug Saf. 1991;6:37–46.

    Article  CAS  PubMed  Google Scholar 

  30. Howland MA. Risks of parenteral deferoxamine. J Toxicol Clin Toxicol. 1996;34:491–7.

    Article  CAS  PubMed  Google Scholar 

  31. Whitten CF, Gibson GW, Good MH, et al. Studies in acute iron poisoning: I. Desferrioxamine in the treatment of acute iron poisoning. Pediatrics. 1965;36:322–35.

    CAS  PubMed  Google Scholar 

  32. Brunner H, Peters G, Jaques R. Wirkungen ven desferrioxamine-methansulfonat auf kreislauf und nierenfunktion. Helv Physiol Pharmacol Acta. 1963;21:C3–6.

    CAS  Google Scholar 

  33. Koren G, Bentur Y, Strong D, et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child. 1989;143:1077–80.

    CAS  PubMed  Google Scholar 

  34. Tenenbein M. Benefits of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol. 1996;34:485–9.

    Article  CAS  PubMed  Google Scholar 

  35. Bentur Y, Koren G, Klein J, et al. Pharmacokinetics and nephrotoxicity of deferoxamine. Vet Hum Toxicol. 1988;30:371.

    Google Scholar 

  36. Scanderbeg AC, Izzi GC, Butturini A, et al. Pulmonary syndrome and intravenous high-dose desferrioxamine. Lancet. 1990;336:1511.

    Article  Google Scholar 

  37. Freedman MH, Grisaru D, Olivieri N, et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child. 1990;144:565–9.

    CAS  PubMed  Google Scholar 

  38. Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet. 1992;379:699–701.

    Article  Google Scholar 

  39. Douglas D, Smilkstein M. Deferoxamine-iron induced pulmonary injury and N-acetylcysteine. J Toxicol Clin Toxicol. 1995;33:495.

    Google Scholar 

  40. Rego EM, Neto EB, Simoes BP, Zago MA. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine (Letter). Am J Hematol. 1998;58:340–1.

    Article  CAS  PubMed  Google Scholar 

  41. Melby K, Slordahal S, Gutteberg TJ, et al. Septicemia due to Yersinia enterocolitica after oral doses of iron. BMJ. 1982;285:487–8.

    Article  Google Scholar 

  42. Gallant T, Freedman MH, Velland H, et al. Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med. 1986;314:1643.

    CAS  PubMed  Google Scholar 

  43. Mofenson HC, Caraccio TR, Sharieff N. Iron sepsis: Yersinia enterocolitica septicemia possibly caused by an overdose of iron. N Engl J Med. 1987;316:1092–3.

    CAS  PubMed  Google Scholar 

  44. Bouza A, Dominguez A, Meseguer M, et al. Yersinia enterocolitica septicemia. Am J Clin Pathol. 1980;74:404–9.

    Article  CAS  PubMed  Google Scholar 

  45. Rabson AR, Halett AF, Koornhof HJ. Generalised Yersinia enterocolitica infection. J Infect Dis. 1975;131:447–51.

    Article  CAS  PubMed  Google Scholar 

  46. Robins-Browne RM, Rabson AR, Koornhof HJ. Generalized infection with Yersinia enterocolitica and the role of iron. Contrib Microbiol Immunol. 1979;5:277–82.

    CAS  PubMed  Google Scholar 

  47. Brock JH, Ng J. The effect of desferrioxamine on the growth of Staphylococcus aureus Yersinia enterocolitica and Streptococcus faecalis in human serum: uptake of desferrioxamine-bound iron. FEMS Microbiol Lett. 1983;2:439–42.

    Article  Google Scholar 

  48. Authanosiou A, Shepp MA, Nechles H. Anaphylactic reaction to deferoxamine. Lancet. 1977;2:616.

    Article  Google Scholar 

  49. Gevirtz NR, Wasserman LR. The measurement of iron and iron-binding capacity in plasma containing deferoxamine. J Pediatr. 1966;68:802–4.

    Article  CAS  PubMed  Google Scholar 

  50. Helfer RE, Rogerson DO. The effect of deferoxamine on the determination of serum iron and iron-binding capacity. J Pediatr. 1966;68:804–6.

    Article  CAS  PubMed  Google Scholar 

  51. Steinmetz WL, Glick MR, Oei TO. Modified aca method for determination of iron chelated by deferoxamine and other chelators. Clin Chem. 1980;26:1593–7.

    CAS  PubMed  Google Scholar 

  52. Fine JS. Iron poisoning. Curr Probl Pediatr. 2000;30:71–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA

    F. Lee Cantrell

Authors
  1. F. Lee Cantrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Lee Cantrell .

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Clinical Pharmacology and Toxicology, University of Colorado, School of Medicine, Aurora, Colorado, USA

    Jeffrey Brent

  2. FDA, Office of New Drugs/Immediate Office, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA

    Keith Burkhart

  3. Clinical Toxicology, St Thomas’ Hospital, Silver Spring, Maryland, USA

    Paul Dargan

  4. Toxicology Associates, University of Colorado, School of Medicine, Denver, Colorado, USA

    Benjamin Hatten

  5. Medical Toxicological Intensive Care Unit, Lariboisiere Hospital, Paris-Diderot University, Paris, France

    Bruno Megarbane

  6. Toxicology Associates, University of Colorado, School of Medicine, Denver, Colorado, USA

    Robert Palmer

  7. Toxinology Department, Women’s and Children’s Hospital, North Adelaide, South Australia, Australia

    Julian White

Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd edition

  1. I

    Evidence obtained from at least one properly randomized controlled trial.

  2. II-1

    Evidence obtained from well-designed controlled trials without randomization.

  3. II-2

    Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.

  4. II-3

    Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.

  5. III

    Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Cantrell, F.L. (2017). Deferoxamine. In: Brent, J., et al. Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-17900-1_170

Download citation

Publish with us

Policies and ethics

Search

Navigation